within Pharmacolibrary.Drugs.ATC.G;

model G02CB01
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.065,
    Cl             = 0.003816,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.1776,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0024333333333333334,
    Tlag           = 600,            
    Vdp             = 1.504,
    k12             = 499.5,
    k21             = 499.5
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G02CB01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Bromocriptine is a dopamine receptor agonist derived from ergot alkaloids. It is used primarily in the treatment of Parkinson's disease, hyperprolactinemia, acromegaly, and type 2 diabetes mellitus. It is an approved medication and is still in clinical use for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters based on healthy adult volunteers (both sexes), single oral dose administration.</p><h4>References</h4><ol><li><p>Friis, ML, et al., &amp; Hvidberg, EF (1979). Pharmacokinetics of bromocriptine during continuous oral treatment of Parkinson&#x27;s disease. <i>European journal of clinical pharmacology</i> 15(4) 275–280. DOI:<a href=&quot;https://doi.org/10.1007/BF00618517&quot;>10.1007/BF00618517</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/477712/&quot;>https://pubmed.ncbi.nlm.nih.gov/477712</a></p></li><li><p>Schran, HF, et al., &amp; Bhuta, SI (1985). Pharmacokinetics and pharmacodynamics of bromocriptine in the rat. <i>Biopharmaceutics &amp; drug disposition</i> 6(3) 301–311. DOI:<a href=&quot;https://doi.org/10.1002/bdd.2510060305&quot;>10.1002/bdd.2510060305</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/4041556/&quot;>https://pubmed.ncbi.nlm.nih.gov/4041556</a></p></li><li><p>Rabey, JM, et al., &amp; Graff, E (1989). The influence of levodopa in the pharmacokinetics of bromocriptine in Parkinson&#x27;s disease. <i>Clinical neuropharmacology</i> 12(5) 440–447. DOI:<a href=&quot;https://doi.org/10.1097/00002826-198910000-00009&quot;>10.1097/00002826-198910000-00009</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2611767/&quot;>https://pubmed.ncbi.nlm.nih.gov/2611767</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G02CB01;
